Effect of CCK-1 antagonist, dexloxiglumide, in female patients with irritable bowel syndrome: a pharmacodynamic and pharmacogenomic study.

What Was Tested

Researchers studied Pentanoic Acids in this randomized controlled trial publication.

Cholecystokinin (CCK) is involved in gastrointestinal motor response to meals.

The potential role of CCK receptor antagonists in functional gastrointestinal disorders is unclear.

Who Took Part

The abstract describes 36 patients taking part.

PubMed indexes the participants as adults, women only.

At the end of treatment, GIT and CT were measured.

How the Study Was Run

The design is described as randomized, double-blind, placebo-controlled and parallel-group.

Random assignment meant chance, not the researchers, decided who got Pentanoic Acids and who got the comparison, which limits bias.

As a double-blind Pentanoic Acids study, the assignments were hidden from both participants and investigators until the end.

The comparison arm used a placebo, so changes seen with Pentanoic Acids could be set against what happens without it.

Groups ran in parallel: each of the patients stayed in one arm throughout.

Peripheral blood DNA was examined for polymorphisms in genes controlling CCK: four related to CCK-1, one to the CCK gene promoter, and one related to CCK-2.

The distributions of allelic variants and association with gastric emptying in response to dexloxiglumide and placebo were assessed.

What Was Measured

Cholecystokinin (CCK) is involved in gastrointestinal motor response to meals.

The potential role of CCK receptor antagonists in functional gastrointestinal disorders is unclear.

Topics PubMed links to this paper include Constipation, Gastric Emptying, Gastrointestinal Transit, Irritable Bowel Syndrome, Patient Compliance, Pentanoic Acids and Polymorphism, Genetic.

What This Means in Plain Language

The paper is a randomized, double-blind and placebo-controlled study of Pentanoic Acids in 36 patients.

With fewer than 40 people, it is a small study, so it is better read as an early signal for further research than as a settled answer.

Its findings take up roughly 5 sentences of the abstract and are left out here on purpose; the source paper is the place to read them.

The publication is from 2005 (The American journal of gastroenterology), a journal based in United States.

More context: all human trials.